WO2006026020A3 - Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin - Google Patents

Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin Download PDF

Info

Publication number
WO2006026020A3
WO2006026020A3 PCT/US2005/027183 US2005027183W WO2006026020A3 WO 2006026020 A3 WO2006026020 A3 WO 2006026020A3 US 2005027183 W US2005027183 W US 2005027183W WO 2006026020 A3 WO2006026020 A3 WO 2006026020A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
oncofetal fibronectin
detection
disease
marker
Prior art date
Application number
PCT/US2005/027183
Other languages
French (fr)
Other versions
WO2006026020A2 (en
WO2006026020A9 (en
Inventor
Robert Hussa
Mark Fischer-Colbrie
Jerome Lapointe
Durlin Hickok
Simon Charles Shorter
Andrew Senyei
Original Assignee
Adeza Biomedical Corp
Robert Hussa
Mark Fischer-Colbrie
Jerome Lapointe
Durlin Hickok
Simon Charles Shorter
Andrew Senyei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adeza Biomedical Corp, Robert Hussa, Mark Fischer-Colbrie, Jerome Lapointe, Durlin Hickok, Simon Charles Shorter, Andrew Senyei filed Critical Adeza Biomedical Corp
Priority to JP2007523875A priority Critical patent/JP2008514900A/en
Priority to EP05810341A priority patent/EP1778874B1/en
Priority to CA002575675A priority patent/CA2575675A1/en
Priority to AU2005280528A priority patent/AU2005280528B2/en
Priority to AT05810341T priority patent/ATE534750T1/en
Publication of WO2006026020A2 publication Critical patent/WO2006026020A2/en
Publication of WO2006026020A9 publication Critical patent/WO2006026020A9/en
Publication of WO2006026020A3 publication Critical patent/WO2006026020A3/en
Priority to HK07111819.9A priority patent/HK1103527A1/en
Priority to AU2011201303A priority patent/AU2011201303B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements

Abstract

Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with anon-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronectin for selection of concepti are provided.
PCT/US2005/027183 2004-07-30 2005-07-29 Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin WO2006026020A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2007523875A JP2008514900A (en) 2004-07-30 2005-07-29 Oncofetal fibronectin as a marker of disease and other conditions and methods for detection of oncofetal fibronectin
EP05810341A EP1778874B1 (en) 2004-07-30 2005-07-29 Oncofetal fibronectin as a marker for cervical cancer
CA002575675A CA2575675A1 (en) 2004-07-30 2005-07-29 Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
AU2005280528A AU2005280528B2 (en) 2004-07-30 2005-07-29 Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
AT05810341T ATE534750T1 (en) 2004-07-30 2005-07-29 ONCOFETAL FIBRONECTIN AS A CERVICAL CARCINOMA MARKER
HK07111819.9A HK1103527A1 (en) 2004-07-30 2007-11-01 Oncofetal fibronectin as a marker for cervical cancer
AU2011201303A AU2011201303B2 (en) 2004-07-30 2011-03-22 Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US59280404P 2004-07-30 2004-07-30
US59282304P 2004-07-30 2004-07-30
US59282504P 2004-07-30 2004-07-30
US59280304P 2004-07-30 2004-07-30
US59282404P 2004-07-30 2004-07-30
US60/592,804 2004-07-30
US60/592,823 2004-07-30
US60/592,825 2004-07-30
US60/592,803 2004-07-30
US60/592,824 2004-07-30

Publications (3)

Publication Number Publication Date
WO2006026020A2 WO2006026020A2 (en) 2006-03-09
WO2006026020A9 WO2006026020A9 (en) 2006-07-06
WO2006026020A3 true WO2006026020A3 (en) 2007-08-16

Family

ID=35841972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027183 WO2006026020A2 (en) 2004-07-30 2005-07-29 Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin

Country Status (10)

Country Link
US (8) US20060024725A1 (en)
EP (2) EP1778874B1 (en)
JP (2) JP2008514900A (en)
AT (1) ATE534750T1 (en)
AU (2) AU2005280528B2 (en)
CA (1) CA2575675A1 (en)
DK (1) DK2299275T3 (en)
HK (1) HK1103527A1 (en)
NZ (1) NZ582466A (en)
WO (1) WO2006026020A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
EP1778874B1 (en) * 2004-07-30 2011-11-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for cervical cancer
JP4306607B2 (en) * 2004-12-24 2009-08-05 富士ゼロックス株式会社 Field effect transistor
US20060239398A1 (en) * 2005-03-07 2006-10-26 Fused Multimodality Imaging, Ltd. Breast diagnostic apparatus for fused SPECT, PET, x-ray CT, and optical surface imaging of breast cancer
ES2291071B1 (en) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. AGENTS AND METHODS BASED ON THE USE OF THE EDA DOMAIN OF FIBRONECTINE.
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US20070255177A1 (en) * 2006-04-27 2007-11-01 Pronovost Allan D Devices and methods for collecting oral samples of enriched serous fluid
US20080108097A1 (en) * 2006-07-24 2008-05-08 National Institute Of Advanced Industrial Science And Technology Method for producing complex of biotin-labeled cypridina (cypridina noctiluca) luciferase with streptoavidin and method for stabilizing the same
BRPI0717416A2 (en) 2006-09-21 2013-11-12 Prometheus Lab Inc METHOD FOR PERFORMING A HIGH PRODUCTIVITY COMPLEX IMMUNOASON, AND
WO2008046510A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
CA2680198C (en) * 2007-03-07 2016-01-19 Mosaiques Diagnostics And Therapeutics Ag Process for normalizing the concentration of analytes in a urine sample
EP1972940A1 (en) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Method and marker for diagnosing kidney disease
US20080241865A1 (en) * 2007-03-26 2008-10-02 National Institute Of Advanced Industrial Science And Technology Visible to near-infrared light probe comprising complex of cypridina luciferase and quantum dot
BRPI0809989B8 (en) 2007-04-02 2021-05-25 Philogen Spa uses of an antibody or antigen-binding fragment thereof that binds to the extradomain isoform-a (ed-a) of fibronectin and/or to the ed-a of fibronectin
CA2693013A1 (en) * 2007-07-13 2009-01-22 Prometheus Laboratories Inc. Drug selection for lung cancer therapy using antibody-based arrays
US8901487B2 (en) 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
CA2691218C (en) * 2007-07-25 2018-04-24 Philogen S.P.A. An antigen associated with lung cancers and lymphomas
EP2198305A2 (en) * 2007-10-09 2010-06-23 Mosaiques Diagnostics And Therapeutics AG Polypeptide marker for the diagnosis of prostate cancer
EP2051078A1 (en) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Method and marker for diagnosing diabetes mellitus
AU2014274545B2 (en) * 2007-10-30 2016-10-13 Philogen S.P.A An antigen associated with rheumatoid arthritis
SI2209805T1 (en) * 2007-10-30 2017-11-30 Philogen S.P.A. An antigen associated with rheumatoid arthritis
SG187453A1 (en) 2008-01-18 2013-02-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
DK2250498T3 (en) 2008-02-25 2013-02-04 Nestec Sa PHARMACEUTICAL CHOICES FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS
JP2011515672A (en) * 2008-03-19 2011-05-19 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー Methods and markers for diagnosis of renal tubular injury and disease
US20110107820A1 (en) * 2008-04-18 2011-05-12 Mark M Kushnir Use of a steroid profile in ovarian follicular fluid for diagnosis, prognosis and determining strategies for treatment
JP5084597B2 (en) * 2008-04-24 2012-11-28 キヤノン株式会社 Mass spectrometry substrate and mass spectrometry method
EP2338054A1 (en) * 2008-09-17 2011-06-29 Mosaiques Diagnostics And Therapeutics AG Kidney cell carcinoma
DE102008053503B4 (en) * 2008-10-28 2011-04-28 Justus-Liebig-Universität Giessen Immunological test for the detection of autoantibodies against testicular antigens
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
WO2010078950A2 (en) * 2009-01-07 2010-07-15 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
WO2010104646A1 (en) * 2009-03-09 2010-09-16 Scott and White Memorial Hospital Method of testing a patient for hypertension and related method of treatment and test kit
GB0906643D0 (en) * 2009-04-17 2009-06-03 Wilson Stuart M Detection of bacteria and fungi
CA2768013C (en) 2009-07-15 2018-08-21 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
JP5828195B2 (en) * 2010-03-11 2015-12-02 ユニバーシティ オブ ルイスビル リサーチ ファンデーション，インコーポレイテッドＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｌｏｕｉｓｖｉｌｌｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ，Ｉｎｃ． Methods for predicting pregnancy loss risk and methods for reducing pregnancy loss risk
CN102309809B (en) * 2010-07-09 2013-11-20 同济大学 Neostomy system
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX2013000917A (en) 2010-07-23 2013-07-05 Harvard College Methods of detecting diseases or conditions using phagocytic cells.
US20120053073A1 (en) 2010-07-23 2012-03-01 President And Fellows Of Harvard College Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids
KR101888213B1 (en) * 2010-10-01 2018-08-13 홀로직, 인크. Immunoassay test strip for use in a diagnostic system
WO2012058463A2 (en) * 2010-10-27 2012-05-03 Dignity Health Trimegestone (tmg) for treatment of preterm birth
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
JP5947533B2 (en) * 2011-01-19 2016-07-06 キヤノン株式会社 Information acquisition method
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
FR2976587B1 (en) * 2011-06-20 2015-04-03 Basf Beauty Care Solutions F IN VITRO DOSING METHOD BY IMMUNOLOGICAL TECHNIQUE
KR101188355B1 (en) 2011-06-24 2012-10-08 광주과학기술원 Separating method of microscopic parts using albumin solution
WO2013085572A2 (en) 2011-07-14 2013-06-13 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
IL214096A (en) * 2011-07-14 2016-02-29 Gideon Mor System for detection of meconium in amniotic fluid
US9523676B2 (en) * 2011-08-24 2016-12-20 Eiken Kagaku Kabushiki Kaisha Leukocyte measurement device and reagent kit
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
CN104380112B (en) 2012-04-13 2017-05-24 迪亚贝托米克斯有限公司 Maternal biomarkers for gestational diabetes
US20140179805A1 (en) 2012-06-15 2014-06-26 Harry Stylli Methods of detecting diseases or conditions
KR102207030B1 (en) * 2012-09-28 2021-01-22 세키스이 메디칼 가부시키가이샤 Additive for measuring diluted sample in non-dilution-type immunochromatographic method reagent
ES2743423T3 (en) 2012-10-03 2020-02-19 Philogen Spa Conjugated antibodies for use in the treatment of an inflammatory bowel disease
EP2909315B1 (en) 2012-10-19 2019-05-01 Wayne State University Identification and analysis of fetal trophoblast cells in cervical mucus for prenatal diagnosis
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
US20140227690A1 (en) * 2013-02-08 2014-08-14 St. John Heallth Methods and compositions for assessment of fetal lung maturity
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2014196803A1 (en) * 2013-06-04 2014-12-11 Proteometech Inc. A strip for rapid testing having a variable control line and a diagnosis kit using the same
MX2016007691A (en) * 2013-12-12 2017-05-01 Umc Utrecht Holding Bv Immunoglobulin-like molecules directed against fibronectin-eda.
CN103743911B (en) * 2013-12-31 2016-01-20 浙江爱康生物科技有限公司 A kind of fibronectin determination kit and preparation method thereof
EP2955517A1 (en) * 2014-06-10 2015-12-16 Siemens Healthcare Diagnostics Products GmbH Process for the stabilisation of body fluid samples by the addition of detergent
US20160025737A1 (en) * 2014-07-25 2016-01-28 Diabetomics, Llc Biomarkers for assessment of preeclampsia
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
EP3177638B1 (en) * 2014-08-04 2019-11-27 Case Western Reserve University Targeting peptides and methods of use
CN106796212A (en) 2014-08-12 2017-05-31 新生代吉恩公司 System and method for monitoring health based on the body fluid collected
AU2015314813B2 (en) 2014-09-11 2022-02-24 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2016057993A1 (en) * 2014-10-10 2016-04-14 Wayne State University Methods and compositions relating to assays of fetal extravillous trophoblast cells
CN104965014B (en) * 2015-07-06 2017-06-23 济南大学 The preparation method of the compound carbon paste electrode of quantum dot/enzyme for detecting SAM
EP3378947B1 (en) * 2015-11-16 2024-01-24 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
US20170176472A1 (en) * 2015-12-17 2017-06-22 Polymer Technology Systems, Inc. Systems and methods for point-of-care hdl and ldl particle assay
KR20180114196A (en) * 2016-02-24 2018-10-17 세키스이 메디칼 가부시키가이샤 Detection of Cancerous Fibronectin Using Immunochromatography
JP6168580B1 (en) * 2016-02-24 2017-07-26 積水メディカル株式会社 Detection method of oncofetal fibronectin using immunochromatography
WO2017170824A1 (en) * 2016-03-31 2017-10-05 積水メディカル株式会社 Oncofetal fibronectin detection method using simple immunoassay
WO2017176985A1 (en) 2016-04-06 2017-10-12 Wayne State University Isolation and analysis of fetal dna from extravillous trophoblast cells retrieved from the endocervical canal
WO2017180909A1 (en) 2016-04-13 2017-10-19 Nextgen Jane, Inc. Sample collection and preservation devices, systems and methods
US10191046B2 (en) * 2016-05-23 2019-01-29 Se-Hwan Paek Immunobiosensor and sensor system including the same
GB2552195A (en) * 2016-07-13 2018-01-17 Univ Oxford Innovation Ltd Interferometric scattering microscopy
CN107330263B (en) * 2017-06-26 2020-07-28 成都知识视觉科技有限公司 Computer-assisted breast invasive ductal carcinoma histological grading method
SG11202002065VA (en) 2017-09-13 2020-04-29 Progenity Inc Preeclampsia biomarkers and related systems and methods
WO2019056020A1 (en) * 2017-09-18 2019-03-21 North Carolina State University Nanocellulose and nanocellulose composite arrays and devices and methods of making and using the same
WO2019118420A1 (en) * 2017-12-11 2019-06-20 Stc. Unm Mild traumatic brain injury diagnostic immunochromatographic microneedle patch
US11798653B2 (en) * 2018-10-18 2023-10-24 Medimmune, Llc Methods for determining treatment for cancer patients
US20210405048A1 (en) * 2018-11-08 2021-12-30 Rochester Institute Of Technology Diagnosing Sepsis or Bacteremia by Detecting Peptidoglycan Associated Lipoprotein (PAL) in Urine
CN111235270B (en) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 Tumor antigen expression detection primer and kit based on high-throughput sequencing method
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111751357B (en) * 2020-07-22 2022-05-24 攀钢集团研究院有限公司 Determination of Fe in a polymorphic iron ion coexisting system in EDTA (ethylene diamine tetraacetic acid) complex denitration liquid2+With Fe3+Method of content
CN111751356B (en) * 2020-07-22 2022-05-24 攀钢集团研究院有限公司 Method for simultaneously determining concentration components of divalent and trivalent iron ions in Fe-EDTA (ethylene diamine tetraacetic acid) complex denitration solution
CN111751355B (en) * 2020-07-22 2022-05-24 攀钢集团研究院有限公司 Method for determining content of ferrous iron ions in Fe (II) -EDTA (ethylene diamine tetraacetic acid) complex denitration liquid
WO2023032925A1 (en) * 2021-08-30 2023-03-09 国立大学法人京都大学 Testing method and testing reagent
WO2023172575A2 (en) * 2022-03-08 2023-09-14 Aeena Dx, Inc. Methods for disease detection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010585A1 (en) * 1990-12-14 1992-06-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal restricted antigens
US5693479A (en) * 1993-03-10 1997-12-02 The Trustees Of The University Of Pennsylvania Fertility determination with transforming growth factor β
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US20030049658A1 (en) * 1999-12-10 2003-03-13 David Smart Assay
EP1293926A2 (en) * 1998-02-03 2003-03-19 Adeza Biomedical Corporation Start control method in a computer system
WO2003036300A2 (en) * 2001-10-26 2003-05-01 University College London Diagnosis of cervical cancer

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US477718A (en) * 1892-06-28 Elevated track or tramway
US522344A (en) * 1894-07-03 John f
US477128A (en) * 1892-06-14 lantz
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US1947171A (en) 1931-05-01 1934-02-13 Prussing Walter Tube making, capping, printing and enameling machine
US4663290A (en) * 1982-01-21 1987-05-05 Molecular Genetics, Inc. Production of reverse transcriptase
US5073484A (en) * 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
US4628027A (en) 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4759376A (en) * 1984-05-29 1988-07-26 Nils Stormby Endocervical sampling brush and smear method
DK8601218A (en) * 1984-07-18 1986-03-17
FR2570703B1 (en) * 1984-09-26 1988-07-08 Commissariat Energie Atomique RARE EARTH MACROPOLYCYCLIC COMPLEXES AND APPLICATION AS FLUORESCENT MARKERS
US4960467A (en) * 1985-02-11 1990-10-02 The United States Of America As Represented By The Secretary Of The Army Dermal substance collection device
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5279943A (en) * 1985-08-02 1994-01-18 Compagnie Oris Industrie Homogeneous process for the detection and/or determination by luminescence of an analyte in a medium in which it may be present
TW203120B (en) 1985-10-04 1993-04-01 Abbott Lab
NL8503596A (en) 1985-12-31 1987-07-16 Futura Nova Bv Apparatus for making a smear from a body cavity.
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
US4777128A (en) * 1986-05-27 1988-10-11 Ethigen Corporation Fluorescence immunoassay involving energy transfer between two fluorophores
US5466591A (en) * 1986-08-22 1995-11-14 Hoffmann-La Roche Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
US4889818A (en) * 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5374553A (en) 1986-08-22 1994-12-20 Hoffmann-La Roche Inc. DNA encoding a thermostable nucleic acid polymerase enzyme from thermotoga maritima
US5455170A (en) * 1986-08-22 1995-10-03 Hoffmann-La Roche Inc. Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5132097A (en) * 1987-02-11 1992-07-21 G.D. Research Apparatus for analysis of specific binding complexes
US4762133A (en) * 1987-03-20 1988-08-09 Medical Dynamics, Inc. Cervical cytology device
CA1303983C (en) * 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
JPS63163167U (en) 1987-04-15 1988-10-25
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4956302A (en) 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
US5096830A (en) * 1987-11-17 1992-03-17 Adeza Biomedical Corporation Preterm labor and membrane rupture test
US5223440A (en) * 1987-11-17 1993-06-29 Adeza Biomedical Corporation Ex vivo product of conception test to determine abortion
CA1337394C (en) 1987-11-17 1995-10-24 Nelson N. H. Teng Vaginal sample test and reagents
US5185270A (en) * 1987-11-17 1993-02-09 Adeza Biomedical Corporation Fetal fibronectin pregnancy test
DE3741201A1 (en) 1987-12-02 1989-06-15 Schering Ag ULTRASONIC PROCESS AND METHOD FOR IMPLEMENTING IT
US5162508A (en) * 1987-12-18 1992-11-10 Compagnie Oris Industrie Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers
US5209904A (en) * 1987-12-23 1993-05-11 Abbott Laboratories Agglutination reaction device utilizing selectively impregnated porous material
US5244797B1 (en) 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
KR970011449B1 (en) 1988-01-29 1997-07-11 더 리전트 오브 디 유니버시티 오브 캘리포니아 Device for iontophoretic non-invasive sampling or delivery of substances
US5362307A (en) * 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
US20030232010A2 (en) 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
SE463188B (en) 1988-05-10 1990-10-22 Stormby Nils BRUSH FOR MEDICAL SAMPLING
US5438984A (en) * 1988-09-08 1995-08-08 Sudor Partners Apparatus and method for the collection of analytes on a dermal patch
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US4919889A (en) * 1988-09-15 1990-04-24 Aspen Diagnostics Corporation Sample collection and transport fluid composition
US5252459A (en) * 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
US5236846A (en) 1988-11-18 1993-08-17 Adeza Biomedical Corporation Ectopic pregnancy test
US5512657A (en) * 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
US5108898A (en) * 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5139023A (en) 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
GB2236186B (en) * 1989-08-22 1994-01-05 Finnigan Mat Gmbh Process and device for laser desorption of analyte molecular ions, especially of biomolecules
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
WO1991016633A1 (en) 1990-04-12 1991-10-31 Adeza Biomedical Corporation Pregnancy induced hypertension and eclampsia immunoassay and reagents
SE9001679L (en) 1990-05-10 1991-09-16 Medscand Ab INSTRUMENTS FOR ENDO- AND ECTOCERVIC SAMPLING
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
FR2664699B1 (en) 1990-07-13 1995-08-18 Cis Bio Int METHOD FOR AMPLIFYING THE EMISSION SIGNAL OF A LUMINESCENT COMPOUND.
ES2134198T3 (en) 1990-09-28 1999-10-01 Hoffmann La Roche MUTATIONS IN THE 5 'TO 3' EXONUCLEASE OF DNA POLYMERASES.
FI86777C (en) 1990-12-31 1992-10-12 Medix Biochemica Ab Oy FOERFARANDE FOER DIAGNOSTICERING AV BRISTNINGEN AV FOSTERHINNORNA SAMT REAGENSFOERPACKNING FOER ANVAENDNING DAERVID
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
FI93607C (en) 1991-05-24 1995-05-10 John Koivukangas Cutting Remedy
WO1993009432A1 (en) 1991-11-04 1993-05-13 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
WO1993009438A1 (en) 1991-11-04 1993-05-13 Adeza Biomedical Corporation Screening method for identifying women at increased risk for preterm delivery
US5516702A (en) * 1991-11-06 1996-05-14 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
US5270166A (en) 1992-03-30 1993-12-14 Abbott Laboratories Immunoassays employing generic anti-hapten antibodies and materials for use therein
WO1993024836A1 (en) 1992-05-29 1993-12-09 Adeza Biomedical Corporation Screening method for identifying women at increased risk for preterm delivery
WO1993024838A1 (en) 1992-05-29 1993-12-09 Adeza Biomedical Corporation Screening method for identifying women at increased risk for preterm delivery
FI94181C (en) 1992-06-29 1995-07-25 Medix Biochemica Ab Oy Diagnostic method for predicting the time of delivery and reagent kit used for it
CA2143292C (en) * 1992-09-28 2002-08-06 Vivian K. Dullien Method for prediction of premature labor
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
CA2152676A1 (en) 1993-01-22 1994-08-04 John C. Leavitt Assay method to rule out rupture of membranes in women at risk for imminent delivery
US5876978A (en) * 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5500375A (en) * 1993-04-13 1996-03-19 Serex, Inc. Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats
US5645537A (en) * 1993-04-20 1997-07-08 Advanced Cytometrix, Inc. Aspiration needle and syringe for use therewith, apparatus incorporating the same and kit for use in fine needle aspiration cytology, and method
EP1347493A3 (en) * 1993-05-28 2005-11-23 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
GB9315847D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tag reagent and assay method
US6056738A (en) 1997-01-31 2000-05-02 Transmedica International, Inc. Interstitial fluid monitoring
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
US5650394A (en) * 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5523229A (en) * 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
US5597700A (en) * 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5658801A (en) 1994-05-03 1997-08-19 Spectral Diagnostics Inc. Medical test kit
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5586981A (en) 1994-08-25 1996-12-24 Xin-Hua Hu Treatment of cutaneous vascular and pigmented lesions
US5548158A (en) 1994-09-02 1996-08-20 National Semiconductor Corporation Structure of bipolar transistors with improved output current-voltage characteristics
US6015668A (en) * 1994-09-30 2000-01-18 Life Technologies, Inc. Cloned DNA polymerases from thermotoga and mutants thereof
US5912155A (en) 1994-09-30 1999-06-15 Life Technologies, Inc. Cloned DNA polymerases from Thermotoga neapolitana
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
WO1996037777A1 (en) 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
US6316266B1 (en) 1995-06-07 2001-11-13 Arizona State University Board Of Regents Sample presentation apparatus for mass spectrometry
US6093541A (en) * 1995-06-07 2000-07-25 Arizona State University Board Of Regents Mass spectrometer having a derivatized sample presentation apparatus
US6004770A (en) 1995-06-07 1999-12-21 Arizona State University Board Of Regents Sample presentation apparatus for mass spectrometry
US5656502A (en) 1995-06-07 1997-08-12 Diagnostic Chemicals Limited Test strip holder and method of use
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6624882B2 (en) 1995-09-08 2003-09-23 Integ, Inc. Methods of sampling body fluid
GB9518429D0 (en) 1995-09-08 1995-11-08 Pharmacia Biosensor A rapid method for providing kinetic and structural data in molecular interaction analysis
US5879367A (en) 1995-09-08 1999-03-09 Integ, Inc. Enhanced interstitial fluid collection
US5948614A (en) 1995-09-08 1999-09-07 Life Technologies, Inc. Cloned DNA polymerases from thermotoga maritima and mutants thereof
US5989409A (en) 1995-09-11 1999-11-23 Cygnus, Inc. Method for glucose sensing
DE69700902T2 (en) 1996-01-23 2000-07-20 Rapigene Inc METHOD FOR DETECTING LIGAND COUPLE BINDING WITH INCREASED SENSITIVITY
US6678669B2 (en) 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US6027939A (en) * 1996-03-08 2000-02-22 Universidad De Las Islas Baleares Process for evaluating the global capacity of urine to form chalky renal calculus, and corresponding kit
US5808300A (en) 1996-05-10 1998-09-15 Board Of Regents, The University Of Texas System Method and apparatus for imaging biological samples with MALDI MS
US6005113A (en) 1996-05-15 1999-12-21 Molecular Probes, Inc. Long wavelength dyes for infrared tracing
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
DE69735445T2 (en) 1996-12-10 2006-08-10 Sequenom, Inc., San Diego NON-VOLATILE, NON-VOLATILE MOLECULES FOR MASS MARKING
CA2441655A1 (en) 1997-01-15 1998-07-23 Xzillion Gmbh & Co Kg Mass label linked hybridisation probes
US6017703A (en) * 1997-03-06 2000-01-25 Bard Diagnostic Sciences, Inc. Methods and compositions for screening for or modulating a tumor associated antigen
ATE486961T1 (en) * 1997-04-03 2010-11-15 Life Technologies Corp METHODS AND PRODUCTS FOR REVERSE TRANSCRIPTION COUPLED WITH POLYMERASE CHAIN REACTION (RT-PCR)
CA2288943C (en) * 1997-04-30 2011-02-01 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
US6156546A (en) 1997-05-16 2000-12-05 Washington State University Research Foundation Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5964735A (en) 1997-07-01 1999-10-12 Medisys Technologies, Inc. Fine needle aspiration safety syringe
US5897840A (en) * 1997-07-16 1999-04-27 Battelle Memorial Institute Multi-chambered urine specimen container for automatic extraction and high forensic integrity
US6436721B1 (en) 1997-07-25 2002-08-20 Bayer Corporation Device and method for obtaining clinically significant analyte ratios
US6503198B1 (en) * 1997-09-11 2003-01-07 Jack L. Aronowtiz Noninvasive transdermal systems for detecting an analyte obtained from or underneath skin and methods
US6221622B1 (en) * 1998-04-28 2001-04-24 The Regents Of The University Of California Method and kit for obtaining fluids and cellular material from breast ducts
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
DE19754978C2 (en) 1997-12-11 2000-07-13 Bruker Daltonik Gmbh Sample holder for MALDI mass spectrometry along with the process for producing the plates and applying the samples
US6844158B1 (en) 1997-12-22 2005-01-18 Hitachi Chemical Co., Ltd. Direct RT-PCR on oligonucleotide-immobilized PCR microplates
EP1045714A1 (en) 1998-01-08 2000-10-25 Sontra Medical, L.P. Sonophoretic enhanced transdermal transport
US6265715B1 (en) * 1998-02-02 2001-07-24 Helene Perreault Non-porous membrane for MALDI-TOFMS
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6173202B1 (en) 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
US6368873B1 (en) * 1998-04-09 2002-04-09 Applied Biotech, Inc. Identification of human urine for drug testing
US6723564B2 (en) * 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
CA2335976A1 (en) 1998-06-24 1999-12-29 Transderm Diagnostics, Inc. Non-invasive transdermal detection of analytes
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
DE19834070B4 (en) 1998-07-29 2007-02-15 Bruker Daltonik Gmbh Ionization of high molecular weight substances by laser desorption from liquid matrices
WO2000011208A1 (en) 1998-08-25 2000-03-02 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
WO2000013573A1 (en) 1998-09-04 2000-03-16 Powderject Research Limited Monitoring methods using particle delivery methods
US6620123B1 (en) 1999-12-17 2003-09-16 Sontra Medical, Inc. Method and apparatus for producing homogenous cavitation to enhance transdermal transport
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6702791B1 (en) 1999-02-04 2004-03-09 Integ, Inc. Needle for body fluid tester
CA2303758C (en) 1999-04-06 2004-01-06 Micromass Limited Improved methods of identifying peptides and proteins by mass spectrometry
US6716636B1 (en) * 1999-04-20 2004-04-06 Target Discovery, Inc. Methods for sequencing proteins
KR100816572B1 (en) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-VEGF antibody and a pharmaceutical composition comprising the same
US6334851B1 (en) * 1999-05-10 2002-01-01 Microfab Technologies, Inc. Method for collecting interstitial fluid from the skin
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
ES2260021T3 (en) 1999-06-08 2006-11-01 Altea Therapeutics Corporation APPARATUS FOR THE MICROPORATION OF BIOLOGICAL MEMBRANES USING DEVICES OF TEXTLE FILM FABRIC INTERFACE, AND ITS METHOD.
US6685699B1 (en) * 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
US6174287B1 (en) * 1999-06-11 2001-01-16 Acuson Corporation Medical diagnostic ultrasound system and method for continuous M-mode imaging and periodic imaging of contrast agents
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US6323186B1 (en) 1999-09-17 2001-11-27 Molecular Probes, Inc. Phosphate-bound polyazaindacene derivatives of nucleotides
AU2088301A (en) * 1999-12-16 2001-06-25 Alza Corporation Device for enhancing transdermal flux of sampled agents
WO2001060448A1 (en) 2000-02-18 2001-08-23 University Of Utah Research Foundation Methods for extracting substances using alternating current
GB0006141D0 (en) 2000-03-14 2000-05-03 Brax Group Ltd Mass labels
US6690976B2 (en) 2000-04-13 2004-02-10 Celsion Corporation Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
AU5867901A (en) 2000-05-04 2001-11-12 Philogen S.R.L. Method for detecting tumors
US6706032B2 (en) 2000-06-08 2004-03-16 Massachusetts Institute Of Technology Localized molecular and ionic transport to and from tissues
WO2001093917A2 (en) * 2000-06-08 2001-12-13 Cytyc Health Corporation Preparation for breast duct fluid collection
US6409679B2 (en) 2000-06-13 2002-06-25 Pacific Paragon Investment Fund Ltd. Apparatus and method for collecting bodily fluid
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
JP3816308B2 (en) 2000-06-19 2006-08-30 ユニ・チャーム株式会社 Disposable diapers
AU2001268363B2 (en) * 2000-06-20 2006-08-17 Biogen Idec Inc. Treatment of B cell associated diseases
US6589173B1 (en) 2000-07-17 2003-07-08 The Regents Of The University Of California Ultrasound system for disease detection and patient treatment
US6673024B2 (en) * 2000-07-28 2004-01-06 Angela Soito Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage
US20020013539A1 (en) * 2000-07-28 2002-01-31 David Hung Methods and devices for diagnosis of precancer and cancer in breast milk ducts
WO2002012900A1 (en) * 2000-08-08 2002-02-14 Cytyc Health Corporation Identification of viral agents in breast ducts and antiviral therapy therefore
IT1317108B1 (en) 2000-12-06 2003-05-26 Philogen Srl PROCESS FOR THE SELECTION OF ANTI-ANGIOGENIC ANTI-CORPORAL FRAGMENTS, ANTI-ANGIOGENIC ANTI-CORPMENTAL FRAGMENTS SO OBTAINED AND THEIR USE.
WO2002057786A2 (en) 2001-01-18 2002-07-25 The Regents Of The University Of Michigan Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
EP1362126A4 (en) * 2001-01-18 2004-07-21 Kemmons A Tubbs An integrated high throughput system for the analysis of biomolecules
US6756200B2 (en) * 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
US6657191B2 (en) 2001-03-02 2003-12-02 Bruker Daltonics Inc. Means and method for multiplexing sprays in an electrospray ionization source
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US7056663B2 (en) * 2001-03-23 2006-06-06 California Pacific Medical Center Prognostic methods for breast cancer
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
WO2003020115A2 (en) 2001-08-31 2003-03-13 Amplistar Inc. Methods and compositions for the detection of cancer
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
AU2002329570A1 (en) * 2001-10-12 2003-01-30 Pfizer Products Inc. Method of monitoring neuroprotective treatment
US20030138823A1 (en) 2001-11-05 2003-07-24 Irm, Llc Sample preparation methods for maldi mass spectrometry
US7094549B2 (en) * 2001-11-23 2006-08-22 Syn X Pharma, Inc. Fibronectin biopolymer marker indicative of insulin resistance
US20030104483A1 (en) * 2001-11-30 2003-06-05 Boehringer Ingelheim Pharmaceuticals, Inc. Liquid chromatography/fourier-transform mass spectrometry/electron capture dissociation for the analysis of proteins
US20030186246A1 (en) 2002-03-28 2003-10-02 Willey James C. Multiplex standardized reverse transcriptase-polymerase chain reacton method for assessment of gene expression in small biological samples
JP4267865B2 (en) 2002-04-19 2009-05-27 株式会社デンソー Load drive device
EP1540341A4 (en) 2002-07-01 2007-01-10 Univ Rochester Medical Ct Method for determination of likelihood of occurrence of preterm labor in pregnant females
WO2004071427A2 (en) 2003-02-06 2004-08-26 Adeza Biomedical Corporation Screening and treatment methods for prevention of preterm delivery
EP1778874B1 (en) 2004-07-30 2011-11-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for cervical cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010585A1 (en) * 1990-12-14 1992-06-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal restricted antigens
US5693479A (en) * 1993-03-10 1997-12-02 The Trustees Of The University Of Pennsylvania Fertility determination with transforming growth factor β
EP1293926A2 (en) * 1998-02-03 2003-03-19 Adeza Biomedical Corporation Start control method in a computer system
US20030049658A1 (en) * 1999-12-10 2003-03-13 David Smart Assay
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003036300A2 (en) * 2001-10-26 2003-05-01 University College London Diagnosis of cervical cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FEINBERG R F ET AL: "Human trophoblasts and tropho-uteronectin (TUN): A model for studying early implantation events", ASSISTED REPRODUCTION REVIEWS 1993 UNITED STATES, vol. 3, no. 1, 1993, pages 19 - 25, XP008063888, ISSN: 1051-2446 *
IAMS JAY D ET AL: "Fetal fibronectin improves the accuracy of diagnosis of preterm labor", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 173, no. 1, 1995, pages 141 - 145, XP002379904, ISSN: 0002-9378 *
LU GEORGE C ET AL: "Vaginal fetal fibronectin levels and spontaneous preterm birth in symptomatic women", OBSTETRICS AND GYNECOLOGY, vol. 97, no. 2, February 2001 (2001-02-01), pages 225 - 228, XP002379903, ISSN: 0029-7844 *
LUTON DOMINIQUE ET AL: "Fetal fibronectin in the cervical secretion predicts accurately the onset of labor at term", EUROPEAN JOURNAL OF OBSTETRICS AND GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol. 74, no. 2, 1997, pages 161 - 164, XP002379905, ISSN: 0301-2115 *
MOUW R J C ET AL: "High cervical fetal-fibronectin concentrations and birth within 3 days in pregnancies of 41 weeks or more", NEW ENGLAND JOURNAL OF MEDICINE 1995 UNITED STATES, vol. 332, no. 16, 1995, pages 1105, XP008063852, ISSN: 0028-4793 *
PEACEMAN ET AL: "Fetal fibronectin as a predictor of preterm birth in patients with symptoms: A multicenter trial", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 177, no. 1, July 1997 (1997-07-01), pages 13 - 17, XP005144649, ISSN: 0002-9378 *
TAKEUCHI K ET AL: "Localization and significance of fibronectin in peri-implantation mouse embryos.", ASIA-OCEANIA JOURNAL OF OBSTETRICS AND GYNAECOLOGY / AOFOG. JUN 1989, vol. 15, no. 2, June 1989 (1989-06-01), pages 191 - 197, XP008063893, ISSN: 0389-2328 *
TURPEENNIEMI-HUJANEN T ET AL: "EXTRACELLULAR MATRIX INTERACTIONS IN EARLY HUMAN EMBRYOS: IMPLICATIONS FOR NORMAL IMPLANTATION EVENTS", FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 64, no. 1, July 1995 (1995-07-01), pages 132 - 138, XP008060802, ISSN: 0015-0282 *
WUNDERLICH H ET AL: "Fetal fibronectin: A new screening-marker for bladder cancer?", ONCOLOGY REPORTS, vol. 8, no. 3, May 2001 (2001-05-01), pages 669 - 672, XP008060794, ISSN: 1021-335X *

Also Published As

Publication number Publication date
US8372581B2 (en) 2013-02-12
US7943294B2 (en) 2011-05-17
EP2299275B1 (en) 2018-03-07
US8852872B2 (en) 2014-10-07
AU2005280528B2 (en) 2010-12-23
US20130171672A1 (en) 2013-07-04
US20120040356A1 (en) 2012-02-16
US20060024724A1 (en) 2006-02-02
AU2011201303A1 (en) 2011-04-07
AU2005280528A1 (en) 2006-03-09
NZ582466A (en) 2011-09-30
ATE534750T1 (en) 2011-12-15
EP1778874B1 (en) 2011-11-23
JP2011039068A (en) 2011-02-24
WO2006026020A2 (en) 2006-03-09
EP2299275A2 (en) 2011-03-23
WO2006026020A9 (en) 2006-07-06
US20060024723A1 (en) 2006-02-02
US9513298B2 (en) 2016-12-06
US20060024757A1 (en) 2006-02-02
EP2299275A3 (en) 2011-08-03
AU2011201303B2 (en) 2012-07-26
JP2008514900A (en) 2008-05-08
DK2299275T3 (en) 2018-05-07
HK1103527A1 (en) 2007-12-21
EP1778874A2 (en) 2007-05-02
US20150044708A1 (en) 2015-02-12
CA2575675A1 (en) 2006-03-09
US20060024722A1 (en) 2006-02-02
US20060024725A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
WO2006126008A3 (en) Improved immunoassay methods
WO2015070037A3 (en) Polynucleotide conjugates and methods for analyte detection
WO2008082979A3 (en) Diagnostic test for the detection of a molecule or drug in whole blood
WO2008039946A3 (en) Integrated meter for analyzing biological samples
WO2006089027A3 (en) Lateral flow test kit and method for detecting an analyte
WO2006014351A3 (en) Exploring fluorophore microenvironments
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
WO2007090126A3 (en) Compositions and methods for detecting and quantifying toxic substances in disease states
WO2007075928A3 (en) Integrated patch and assay device with visual detection means
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
WO2005003732A3 (en) Diagnostic test for analytes in a sample
DE602005013225D1 (en) APTAMER NANOPARTICLE CONJUGATES AND USE METHOD FOR THE DETECTION OF TARGET ANALYSTS
WO2006135818A8 (en) Recirculating microfluidic device and methods of use
BRPI0707645B8 (en) in vitro methods for detecting cancer in an individual and for evaluating the prognosis of an individual having, or suspected of having, ovarian cancer
WO2005084210A3 (en) Multiplex detection probes
WO2008135862A3 (en) Devices and methods for detecting analytes
GB0319376D0 (en) Histone modification detection
WO2007133586A3 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2008089072A3 (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2007061940A3 (en) Method for detecting an inflammatory disease or cancer
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2009086186A3 (en) Automated method and apparatus for detecting erroneous sample collection in clinical assays

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 552244

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005280528

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005810341

Country of ref document: EP

Ref document number: 2575675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007523875

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001213

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005280528

Country of ref document: AU

Date of ref document: 20050729

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005280528

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005810341

Country of ref document: EP